SCHEMBL8042811

SCHEMBL8042811

C=CCc1c(F)cccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.55
GAA P10253 1/20 0.52
BACE1 P56817 1/20 0.49
HTT P42858 2/20 0.45
KDM4E B2RXH2 2/20 0.44
CYP2A13 Q16696 1/20 0.44
ATM Q13315 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
DAO P14920 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9221316 0.85 TAAR1 (0.39) TAAR1GAABACE1HTTKDM4E
SCHEMBL249069 0.85 TAAR1 (0.44) TAAR1GAATDP1KMT2AMEN1
SCHEMBL27479766 0.85 TAAR1 (0.52) TAAR1GAABACE1HTTKDM4E
SCHEMBL1460113 0.80 TAAR1 (0.55) TAAR1GAABACE1HTTKDM4E
SCHEMBL29569478 0.80 TAAR1 (0.55) TAAR1GAABACE1HTTKDM4E
SCHEMBL145823 0.77 TAAR1 (0.61) TAAR1GAABACE1HTTKDM4E
SCHEMBL4276097 0.76 TAAR1 (0.33) TAAR1GAABACE1CYP2A13HPGD
SCHEMBL17097240 0.76 EED (0.37) TAAR1GAABACE1HTTKDM4E
SCHEMBL4926856 0.76 GABRA1 (0.41) TAAR1GAABACE1HTTKDM4E
SCHEMBL29728153 0.76 ACHE (0.43) TAAR1GAAKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968211-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
WO-2009068246-A2 METHODS OF TREATING OBESITY AND METABOLIC DISORDERS ELBION GMBH (DE) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 TAAR1 2610/4885GAA 3679/4885BACE1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.